Agios to Present Data From the Phase 3 ClarIDHy Study of TIBSOVO® in Previously Treated IDH1 Mutant Cholangiocarcinoma in Presidential Symposium at ESMO

On September 10, 2019 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, reported that results from the Phase 3 ClarIDHy study of TIBSOVO in previously treated IDH1 mutant cholangiocarcinoma have been accepted for presentation in a Presidential Symposium at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Annual Meeting being held September 27 – October 1, 2019 in Barcelona (Press release, Agios Pharmaceuticals, SEP 10, 2019, View Source [SID1234539425]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The schedule for the presentation by Agios is as follows:

Date & Time: Monday, September 30, 2019 from 4:30 p.m. – 4:42 p.m. CET
Title: ClarIDHy: A global, phase 3, randomized, double-blind study of ivosidenib vs placebo in patients with advanced cholangiocarcinoma with an isocitrate dehydrogenase 1 (IDH1) mutation
Oral Abstract Session: Presidential Symposium III
Abstract: LBA10
Location: Barcelona Auditorium (Hall 2)
Presenter: Ghassan K. Abou-Alfa, Memorial Sloan-Kettering Cancer Center

Conference Call Information
Agios will host a conference call and live webcast with presentation slides on September 30, 2019 at 1 p.m. ET /7 p.m. CET to discuss the data from the ClarIDHy study. To participate in the conference call, please dial 1-877-377-7098 (domestic) or 1-631-291-4547 (international) and refer to conference ID 5209309. The live webcast can be accessed under "Events & Presentations" in the Investors section of the company’s website at www.agios.com. The archived webcast will be available on the company’s website beginning approximately two hours after the event.